Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

11.70USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$11.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
37,283
52-wk High
$18.00
52-wk Low
$7.50

Latest Key Developments (Source: Significant Developments)

Eiger Biopharmaceuticals Inc Qtrly Loss Per Share $0.82
Friday, 10 Aug 2018 07:41am EDT 

Aug 10 (Reuters) - Eiger BioPharmaceuticals Inc ::QTRLY LOSS PER SHARE $0.82.Q2 EARNINGS PER SHARE VIEW $-0.82 -- THOMSON REUTERS I/B/E/S.  Full Article

Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock
Wednesday, 23 May 2018 04:15pm EDT 

May 23 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EIGER BIOPHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.EIGER BIOPHARMACEUTICALS - PLANS TO USE NET PROCEEDS TO FUND PLANNED PHASE 3 CLINICAL TRIAL OF LONAFARNIB IN HEPATITIS DELTA VIRUS INFECTION, OTHERS.  Full Article

Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results
Friday, 11 May 2018 08:00am EDT 

Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.84.Q1 EARNINGS PER SHARE VIEW $-1.04 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, EIGER HAD CASH, CASH EQUIVALENTS AND SHORT-TERM DEBT SECURITIES OF $33.2 MILLION.  Full Article

Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​
Wednesday, 21 Mar 2018 08:00am EDT 

March 21 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM.EIGER BIOPHARMACEUTICALS INC - ‍PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018​.EIGER BIOPHARMACEUTICALS INC - PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018.EIGER BIOPHARMACEUTICALS INC - EXPECT TO SHARE ADDITIONAL INFORMATION ON PLANNED REGISTRATION PROGRAM IN 2Q 2018.EIGER BIOPHARMACEUTICALS - ‍LIFT ENROLLMENT PLANNED FOR 2Q 2018​.  Full Article

Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
Tuesday, 16 Jan 2018 08:00am EST 

Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018.EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS.EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH.EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS.EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY.  Full Article

‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​
Thursday, 9 Nov 2017 09:07am EST 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing.  Full Article

Eiger Biopharmaceuticals reports Q3 loss per share $1.10
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.10.Q3 earnings per share view $-1.28 -- Thomson Reuters I/B/E/S.Eiger Biopharmaceuticals - ‍As of Sept 30, 2017, Eiger had cash, cash equivalents and short-term marketable securities of $32.3 million.Eiger Biopharmaceuticals Inc - ‍Company estimates its cash runway now extends into mid-2019​.  Full Article

EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Friday, 27 Oct 2017 09:17am EDT 

Oct 27 (Reuters) - Eiger Biopharmaceuticals Inc :EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.8 MILLION SHARES AT $10.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS & COMMISSIONS​.  Full Article

Eiger BioPharmaceuticals announces proposed public offering of common stock
Thursday, 26 Oct 2017 04:30pm EDT 

Oct 26 (Reuters) - Eiger BioPharmaceuticals Inc :Eiger BioPharmaceuticals announces proposed public offering of common stock.Eiger BioPharmaceuticals - ‍intends to use net proceeds of offering to fund clinical development of its portfolio of four product candidates​.  Full Article

Eiger says FDA orphan drug designation granted for pegylated interferon lambda in hepatitis delta virus infection
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Eiger Biopharmaceuticals Inc ::Eiger announces FDA orphan drug designation granted for pegylated interferon lambda in hepatitis delta virus infection.  Full Article